Iranian Journal of Immunology

Camrelizumab plus zoledronic acid showed sustained efficacy in a patient with cranial and spinal metastases from lung adenocarcinoma

Document Type : Case Report

Authors

Chu Zhang 1
Guangmao Yu 1
Miao Zhang 2
Wenbin Wu 2

1 Department of Thoracic Surgery, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, P.R.China

2 Department of Thoracic Oncology, Xuzhou Central Hospital, Xuzhou, P.R.China

https://doi.org/10.22034/iji.2021.87760.1828
Abstract
The role of anti-programmed cell death protein-1 (PD-1) antibody camrelizumab in brain metastases (BMs) from lung adenocarcinoma is uncertain. Herein, for the first time, we report the efficacy of camrelizumab in a patient with chemotherapy-refractory BMs from lung adenocarcinoma. A 49-year-old male non-smoker was admitted with cough and back pain. Primary lung adenocarcinoma with brain and spinal metastases was diagnosed. The specimen from CT-guided lung biopsy showed positive expression of PD-L1 (~20%). The BMs were enlarged after first-line intravenous pemetrexed/cisplatin and zoledronic acid; whereas second-line camrelizumab demonstrated impressive complete remission of the BMs. The intracranial progression-free survival and overall survival of the patient since immunotherapy were more than 12 months and 20 months, respectively. In addition, we searched PubMed for relevant studies from inception to May 2020, and a total of 23 reports enrolling 1187 patients also indicated the promising efficacy of immunotherapy for BMs from lung cancer. However, more and better evidence are still needed before a definite conclusion could be drawn.

Keywords

programmed cell death protein-1 (PD-1)
anti-PD-1 monoclonal antibody
immune checkpoint inhibitors (ICIs)
brain metastasis
Iranian Journal of Immunology
Volume 18, Issue 2
Spring 2021
Pages 150-157

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us